Impax Laboratories, Inc. (NASDAQ: IPXL) today announced two executive appointments that will strengthen the company’s leadership in the critical areas of operations and quality affairs. The company has appointed Mark Fitch as Senior Vice President Global Operations and Jeff Nornhold as Senior Vice President Global Quality Affairs. Both Mr. Fitch and Mr. Nornhold will report to Impax’s President and Chief Executive Officer, Larry Hsu, Ph.D.

Mr. Fitch brings over 35 years of pharmaceutical experience to his role at Impax. He joins the company from Nycomed US, where he was Senior Vice President Operations. Prior to joining Nycomed, he was a consultant in the pharmaceutical industry, and before that he spent 10 years with Mylan Pharmaceuticals as a member of the executive team that led Mylan through its critical growth period, including key acquisitions. During his tenure with Mylan, he was responsible for all manufacturing plant operations, facilities engineering, maintenance, safety, security and technical support at solid dosage form plants in West Virginia and Puerto Rico. He earned his Bachelor of Science degree in pharmacy and pharmaceutical sciences at Purdue University.

Mr. Nornhold, who has 20 years of pharmaceutical industry experience, joins Impax from Watson Pharmaceuticals, Inc., where he was most recently Vice President, Quality Operations – International, and was responsible for outside of the U.S. manufacturing sites for both dosage and active pharmaceutical ingredients. While at Watson, he also served as Vice President U.S. Quality Operations leading the development and execution of quality initiatives for all U.S. sites. Prior to joining Watson in 2000, he held numerous leadership positions within the pharmaceuticals industry. He earned a Bachelor of Science degree in chemistry from Bowling Green State University and a Master’s in Business Administration from the University of Southern California Marshall School of Business.

“We are very pleased that Mark and Jeff have joined Impax to oversee these two very critical areas of our business,” said Larry Hsu, Ph.D., president and CEO of Impax. “They are accomplished executives with a strong track record and extensive pharmaceutical and business leadership experience. We have experienced significant growth the past several years and their addition further enhances our management team.”

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (“Impax”) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. For more information, please visit the Company's Website at: www.impaxlabs.com.

Copyright Business Wire 2010